29 апреля 2020 года в 18:05 в дистанционном формате состоялась лекция ведущего эксперта в области наносистем и наномедицины, руководителя одного из первых «мегагрантов» и основателя уникальной лаборатории «Химический дизайн бионаноматериалов» на химическом факультете МГУ, члена–корреспондента РАН, профессора МГУ А.В. Кабанова "Super-High Capacity Polymeric Micelles for Cancer Therapeutics... and Few Words about Covid-19 Therapeutics".
Прямая трансляция - на ресурсах "Научной России" (Scientific Russia): https://scientificrussia.ru/news/ekspert-v-oblasti-nanosistem-i-nanomeditsiny-aleksandr-kabanov
Ведущий эксперт в области доставки лекарств с использованием полимерных наносистем. В лекции будет рассказано о полимерных мицеллах сверхвысокой загрузки для доставки лекарств для лечения рака и немного о терапевтических подходах к лечению коронавируса covid-19.
Александр Викторович – не только представитель и университетского, и академического сообществ в России, но и один из инициаторов Президентской программы поддержки ученых, реализуемой в настоящий момент Российским научным фондом, он является одновременно и заслуженным профессором фармацевтического факультета, директором центра нанотехнологий для доставки лекарств университета Северной Каролины и института наномедицины Каролины, президентом Русско-Американской научной ассоциации (RASA-USA), а также членом Европейской академии, Национальной академии изобретателей США (National Academy of Inventors), Американского института медицинской и биологической инженерии (American Institute for Medical and Biological Engineering), членом совета директоров и действительным членом Общества контролируемой доставки (ControlledReleaseSociety).
Super-High Capacity Polymeric Micelles for Cancer Therapeutics…and Few Words about Covid-19 Therapeutics
Alexander Kabanov (Center for Nanotechnology in Drug Delivery and Carolina Institute for Nanomedicine, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA; Laboratory for Chemical Design of Bionanomaterials, M.V. Lomonosov Moscow State University, Moscow, Russia 117296 e-Mail: kabanov@unc.edu)
Poly(2-oxazoline) polymeric micelles (PM) display unprecedented high loading with respect to water-insoluble active pharmaceutical ingredients (APIs). This drug delivery platform greatly enhances the solubility and stability of drugs and drug candidates and improves their efficacy and safety in a transformative way. The technology has been validated for more than 20 extremely poorly soluble APIs. The injectable aqueous solutions are readily prepared that are stable and contain up to 50-100 g/L of extremely poorly soluble APIs, at least 10 to 100 times greater amounts than most other solubilization methods. The drug to excipient ratio in poly(2-oxazoline) PM is also 10 to 100 times better than the ratios of excipients in other approaches. One example is a Cremophor- and PEG-free paclitaxel in poly(2-oxazoline) PM. It has demonstrated potential to increase treatment efficacy of cancers by using high-dose therapy and shown superiority in treatment of tumors in animal models when compared to marketed paclitaxels. For many of the drug candidates poly(2-oxazoline) PM platform represents the only possibility for a parenteral drug application and enables major contribution to patient care. Chemo-sensitizing agents and agents modifying tumor microenvironment in poly(2-oxazoline) PM were shown to improve chemo- and immunotherapy of cancers in both prevalent and orphan diseases in animal models. Poly(2-oxazoline) PM platform allows easy co-formulation of multiple APIs to 1) decrease burden of administering these APIs separately to a patient in combination drug therapy, and 2) improve treatment efficacy by simultaneous delivery of these APIs to biological targets. Superior antitumor activity of PM with co-loaded drugs compared to single drug micelles or their combination was demonstrated. A rational, computer-aided approach to reliable selection of hydrophobic molecules with dramatically improved solubility in poly(2-oxazoline) PM was developed to enhance the throughput and success of formulation development for new APIs. The work has been supported by the United States National Institutes of Health (1U54CA198999).
Alexander Kabanov, a Distinguished Professor at the Eshelman School of Pharmacy, UNC-Chapel Hill, director of Center for Nanotechnology in Drug Delivery and Carolina Institute for Nanomedicine. Professor of Chemistry Department, Moscow State University. Pioneered the use of polymeric micelles, DNA/polycation complexes, nanogels, macrophage carriers and exosomes for delivery of drugs, nucleic acids and polypeptides. Published over 300 scientific papers, holds 35 US patents and co-founded several pharmaceutical companies. 1988 Lenin Komsomol Prize, 2010 Russian Megagrant and 2018 George Gamow award. Elected to Academia Europaea, US National Academy of Inventors, and Russian Academy of Sciences (corresponding member). President of Russian American Science Association.
Дополнительная информация:
- Расписание ближайших лекций: http://www.nanometer.ru/2020/04/26/ras_530235.html
- Youtube канал проекта "Академия - Университетам": https://www.youtube.com/channel/UCQvv1SNCtLVav4yLlMvt5sw
- Youtube канал проекта дистанционного образования факультета наук о материалах МГУ имени М.В.Ломоносова: https://www.youtube.com/channel/UCepiCWoe2ew8ID901LL4Fkg
